WallStreetZenWallStreetZen

NASDAQ: VERU
Veru Inc Stock Forecast, Predictions & Price Target

Analyst price target for VERU

Based on 4 analysts offering 12 month price targets for Veru Inc.
Min Forecast
$3.00+216.79%
Avg Forecast
$4.00+322.39%
Max Forecast
$5.00+427.98%

Should I buy or sell VERU stock?

Based on 4 analysts offering ratings for Veru Inc.
Strong Buy
Strong Buy
1 analysts 25%
Buy
3 analysts 75%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VERU stock forecasts and price targets.

VERU stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-14
lockedlocked$00.00+00.00%2024-05-13
lockedlocked$00.00+00.00%2024-04-15
lockedlocked$00.00+00.00%2024-03-28

1 of 1

Forecast return on equity

Is VERU forecast to generate an efficient return?
Company
-118.18%
Industry
73.55%
Market
80.54%
VERU's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VERU forecast to generate an efficient return on assets?
Company
-74.41%
Industry
31.45%
VERU is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VERU earnings per share forecast

What is VERU's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$0.27
Avg 2 year Forecast
-$0.30
Avg 3 year Forecast
-$0.37

VERU revenue forecast

What is VERU's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$13.3M-1.06%
Avg 2 year Forecast
$12.0M-11.27%
Avg 3 year Forecast
$9.0M-33.23%
VERU's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VERU revenue growth forecast

How is VERU forecast to perform vs Biotechnology companies and vs the US market?
Company
-10.92%
Industry
37.19%
Market
10.57%
VERU's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VERU's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VERU vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VERU$0.95$4.00+322.39%Strong Buy
IMAB$1.72$8.00+365.12%Strong Buy
GALT$2.24$11.00+391.07%Buy
IVA$2.68$22.33+733.32%Strong Buy
CAPR$4.40$21.75+394.32%Strong Buy

Veru Stock Forecast FAQ

Is Veru Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: VERU) stock is to Strong Buy VERU stock.

Out of 4 analysts, 1 (25%) are recommending VERU as a Strong Buy, 3 (75%) are recommending VERU as a Buy, 0 (0%) are recommending VERU as a Hold, 0 (0%) are recommending VERU as a Sell, and 0 (0%) are recommending VERU as a Strong Sell.

If you're new to stock investing, here's how to buy Veru stock.

What is VERU's earnings growth forecast for 2024-2026?

(NASDAQ: VERU) Veru's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.02%.

Veru's earnings in 2024 is -$35,819,536.On average, 5 Wall Street analysts forecast VERU's earnings for 2024 to be -$38,938,123, with the lowest VERU earnings forecast at -$42,451,337, and the highest VERU earnings forecast at -$35,132,141. On average, 5 Wall Street analysts forecast VERU's earnings for 2025 to be -$44,207,944, with the lowest VERU earnings forecast at -$46,842,854, and the highest VERU earnings forecast at -$40,987,498.

In 2026, VERU is forecast to generate -$53,430,131 in earnings, with the lowest earnings forecast at -$55,625,890 and the highest earnings forecast at -$51,234,372.

What is VERU's revenue growth forecast for 2024-2026?

(NASDAQ: VERU) Veru's forecast annual revenue growth rate of -10.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.57%.

Veru's revenue in 2024 is $13,479,224.On average, 5 Wall Street analysts forecast VERU's revenue for 2024 to be $1,952,175,957, with the lowest VERU revenue forecast at $1,507,754,376, and the highest VERU revenue forecast at $2,781,294,480. On average, 5 Wall Street analysts forecast VERU's revenue for 2025 to be $1,750,751,683, with the lowest VERU revenue forecast at $1,171,071,360, and the highest VERU revenue forecast at $2,839,848,048.

In 2026, VERU is forecast to generate $1,317,455,280 in revenue, with the lowest revenue forecast at $1,171,071,360 and the highest revenue forecast at $1,463,839,200.

What is VERU's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: VERU) forecast ROA is -74.41%, which is lower than the forecast US Biotechnology industry average of 31.45%.

What is VERU's Price Target?

According to 4 Wall Street analysts that have issued a 1 year VERU price target, the average VERU price target is $4.00, with the highest VERU stock price forecast at $5.00 and the lowest VERU stock price forecast at $3.00.

On average, Wall Street analysts predict that Veru's share price could reach $4.00 by May 14, 2025. The average Veru stock price prediction forecasts a potential upside of 322.39% from the current VERU share price of $0.95.

What is VERU's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: VERU) Veru's current Earnings Per Share (EPS) is -$0.34. On average, analysts forecast that VERU's EPS will be -$0.27 for 2024, with the lowest EPS forecast at -$0.29, and the highest EPS forecast at -$0.24. On average, analysts forecast that VERU's EPS will be -$0.30 for 2025, with the lowest EPS forecast at -$0.32, and the highest EPS forecast at -$0.28. In 2026, VERU's EPS is forecast to hit -$0.37 (min: -$0.38, max: -$0.35).

What is VERU's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: VERU) forecast ROE is -118.18%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.